DARZALEX (daratumumab) for injection is used for the treatment of patients with multiple myeloma (bone marrow cancer).

DARZALEX is a CD38-directed cytolytic antibody indicated: • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy • as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are doublerefractory to a PI and an immunomodulatory agent.

DARZALEX (daratumumab) for injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of DARZALEX (daratumumab) for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the DARZALEX (daratumumab) for injection medicine cost price in India.

The order for DARZALEX (daratumumab) for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress.
In November 2015, the U.S. Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in patients who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.
In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
In May 2018, the FDA expanded the approval of daratumumab for use in combination with bortezomib, melphalan and prednisone to include the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

DARZALEX (daratumumab) injection, for intravenous use. Initial U.S. Approval – 2015

Generic Name: daratumumab

Injection: • 100 mg/5 mL solution in a single-dose vial
• 400 mg/20 mL solution in a single-dose vial

DARZALEX (daratumumab) injection

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to DARZALEX (daratumumab) on the Named Patient Import basis in India.

DARZALEX (daratumumab)

News / Update for DARZALEX (daratumumab) for injection.

For DARZALEX (daratumumab) for injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

More good news for Janssen’s Darzalex For More Details

CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma For More Details

DARZALEX (daratumumab) manufacturer and suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand DARZALEX (daratumumab) on prescription and Import License in Patient's Name only.

For overseas patients, DARZALEX (daratumumab) can be made available in Send your enquiry to find DARZALEX (daratumumab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

Steps to access DARZALEX (daratumumab) on the Named Patient Import basis.

Step 1.
You send a request for your medicine online:-
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.

Step 2.
We verify your prescription and medical details:-
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.

Step 3.
We source your medicine:-
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 4.
We deliver your medicine:-
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation for Named-Patient import to access DARZALEX (daratumumab).

Doctor’s Prescription –
We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

Room temperature shipping

For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

IPN, Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified professionals of pharmaceutical Industry. Registration Number :07AAFFI2544E1ZO under GST Act. Specialized in Oncology Pharmacy. Helped more than 6,000 patients.

Helps you access to a FDA approved medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery.

IPN, New Delhi a trusted pharmaceutical exporter and wholesaler for Anti-Cancer Medicines in India.
Branch Office in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jodhpur